Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis

E. S. Dellon, L. L. Higgins, R. Beitia, S. Rusin, J. T. Woosley, R. Veerappan, S. R. Selitsky, J. S. Parker, R. M. Genta, R. H. Lash, R. Aranda, R. J. Peach, M. Grimm

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background Periostin is highly expressed in eosinophilic oesophagitis (EoE), but has not been extensively studied as a non-invasive biomarker. Aim To assess whether serum periostin distinguished EoE from controls at baseline, had utility for monitoring treatment response, or was associated with IL-13 levels. Methods This was a sub-analysis of a prospective cohort study of adults undergoing out-patient upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 and tissue expression of periostin were also assessed. Results A total of 61 incident EoE cases and 87 controls were analysed. Despite a marked increase in tissue periostin expression in cases, the median baseline serum periostin level was only slightly higher in cases than controls (22.1 ng/mL vs. 20.7; P = 0.04); there was no change in post-treatment levels. There was also no difference in serum periostin for cases by histologic response or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest periostin quartile (57.1 pg/mL vs. 2.6; P = 0.07). Conclusions Serum periostin levels were similar in cases and controls, and there were no changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-IL-13 therapy.

Original languageEnglish (US)
Pages (from-to)189-197
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume44
Issue number2
DOIs
StatePublished - Jul 1 2016

Fingerprint

Eosinophilic Esophagitis
Biomarkers
Interleukin-13
Serum
Endoscopy
Therapeutics
Deglutition Disorders
Gastroesophageal Reflux
Cohort Studies
Outpatients
Steroids
Prospective Studies
Guidelines
Biopsy

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Dellon, E. S., Higgins, L. L., Beitia, R., Rusin, S., Woosley, J. T., Veerappan, R., ... Grimm, M. (2016). Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis. Alimentary Pharmacology and Therapeutics, 44(2), 189-197. https://doi.org/10.1111/apt.13672

Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis. / Dellon, E. S.; Higgins, L. L.; Beitia, R.; Rusin, S.; Woosley, J. T.; Veerappan, R.; Selitsky, S. R.; Parker, J. S.; Genta, R. M.; Lash, R. H.; Aranda, R.; Peach, R. J.; Grimm, M.

In: Alimentary Pharmacology and Therapeutics, Vol. 44, No. 2, 01.07.2016, p. 189-197.

Research output: Contribution to journalArticle

Dellon, ES, Higgins, LL, Beitia, R, Rusin, S, Woosley, JT, Veerappan, R, Selitsky, SR, Parker, JS, Genta, RM, Lash, RH, Aranda, R, Peach, RJ & Grimm, M 2016, 'Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis', Alimentary Pharmacology and Therapeutics, vol. 44, no. 2, pp. 189-197. https://doi.org/10.1111/apt.13672
Dellon, E. S. ; Higgins, L. L. ; Beitia, R. ; Rusin, S. ; Woosley, J. T. ; Veerappan, R. ; Selitsky, S. R. ; Parker, J. S. ; Genta, R. M. ; Lash, R. H. ; Aranda, R. ; Peach, R. J. ; Grimm, M. / Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis. In: Alimentary Pharmacology and Therapeutics. 2016 ; Vol. 44, No. 2. pp. 189-197.
@article{350d1bc4d27a46fb9682aad581f0f9f8,
title = "Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis",
abstract = "Background Periostin is highly expressed in eosinophilic oesophagitis (EoE), but has not been extensively studied as a non-invasive biomarker. Aim To assess whether serum periostin distinguished EoE from controls at baseline, had utility for monitoring treatment response, or was associated with IL-13 levels. Methods This was a sub-analysis of a prospective cohort study of adults undergoing out-patient upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 and tissue expression of periostin were also assessed. Results A total of 61 incident EoE cases and 87 controls were analysed. Despite a marked increase in tissue periostin expression in cases, the median baseline serum periostin level was only slightly higher in cases than controls (22.1 ng/mL vs. 20.7; P = 0.04); there was no change in post-treatment levels. There was also no difference in serum periostin for cases by histologic response or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest periostin quartile (57.1 pg/mL vs. 2.6; P = 0.07). Conclusions Serum periostin levels were similar in cases and controls, and there were no changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-IL-13 therapy.",
author = "Dellon, {E. S.} and Higgins, {L. L.} and R. Beitia and S. Rusin and Woosley, {J. T.} and R. Veerappan and Selitsky, {S. R.} and Parker, {J. S.} and Genta, {R. M.} and Lash, {R. H.} and R. Aranda and Peach, {R. J.} and M. Grimm",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/apt.13672",
language = "English (US)",
volume = "44",
pages = "189--197",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis

AU - Dellon, E. S.

AU - Higgins, L. L.

AU - Beitia, R.

AU - Rusin, S.

AU - Woosley, J. T.

AU - Veerappan, R.

AU - Selitsky, S. R.

AU - Parker, J. S.

AU - Genta, R. M.

AU - Lash, R. H.

AU - Aranda, R.

AU - Peach, R. J.

AU - Grimm, M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background Periostin is highly expressed in eosinophilic oesophagitis (EoE), but has not been extensively studied as a non-invasive biomarker. Aim To assess whether serum periostin distinguished EoE from controls at baseline, had utility for monitoring treatment response, or was associated with IL-13 levels. Methods This was a sub-analysis of a prospective cohort study of adults undergoing out-patient upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 and tissue expression of periostin were also assessed. Results A total of 61 incident EoE cases and 87 controls were analysed. Despite a marked increase in tissue periostin expression in cases, the median baseline serum periostin level was only slightly higher in cases than controls (22.1 ng/mL vs. 20.7; P = 0.04); there was no change in post-treatment levels. There was also no difference in serum periostin for cases by histologic response or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest periostin quartile (57.1 pg/mL vs. 2.6; P = 0.07). Conclusions Serum periostin levels were similar in cases and controls, and there were no changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-IL-13 therapy.

AB - Background Periostin is highly expressed in eosinophilic oesophagitis (EoE), but has not been extensively studied as a non-invasive biomarker. Aim To assess whether serum periostin distinguished EoE from controls at baseline, had utility for monitoring treatment response, or was associated with IL-13 levels. Methods This was a sub-analysis of a prospective cohort study of adults undergoing out-patient upper endoscopy. Incident cases of EoE were diagnosed per consensus guidelines. Controls were subjects with either GERD or dysphagia without EoE. EoE patients were treated with swallowed/topical steroids and had repeat endoscopy/biopsy. Serum periostin levels for cases and controls were compared at baseline, and pre/post-treatment levels were compared for cases. Serum IL-13 and tissue expression of periostin were also assessed. Results A total of 61 incident EoE cases and 87 controls were analysed. Despite a marked increase in tissue periostin expression in cases, the median baseline serum periostin level was only slightly higher in cases than controls (22.1 ng/mL vs. 20.7; P = 0.04); there was no change in post-treatment levels. There was also no difference in serum periostin for cases by histologic response or atopic status. There was a strong trend towards higher serum IL-13 levels in cases in the highest periostin quartile (57.1 pg/mL vs. 2.6; P = 0.07). Conclusions Serum periostin levels were similar in cases and controls, and there were no changes post-treatment. Given elevated IL-13 levels in the EoE patients with the highest periostin levels, future studies could explore periostin as a biomarker in EoE, perhaps in the setting of anti-IL-13 therapy.

UR - http://www.scopus.com/inward/record.url?scp=84970996488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970996488&partnerID=8YFLogxK

U2 - 10.1111/apt.13672

DO - 10.1111/apt.13672

M3 - Article

VL - 44

SP - 189

EP - 197

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -